Orladeyo.com

Keyword Suggestion

Orladeyo

Orladeyo drug

Orladeyo storage

Orladeyo price

Orladeyo package insert

Orladeyo atc code

Orladeyo dosage

Orladeyo ema

Orladeyo functions

Orladeyo fda

Orladeyo expiry date

Orladeyo formula

Orladeyo fda label

Orladeyo side effects

Orladeyo chemical representation

Orladeyo prescribing information

Orladeyo.com lookup results from whois.godaddy.com server:

Network

Owner

Abuse

Technical support

Domain Provider	Number Of Domains
godaddy.com	286730
namecheap.com	101387
networksolutions.com	69118
tucows.com	52617
publicdomainregistry.com	39120
whois.godaddy.com	32793
enomdomains.com	23825
namesilo.com	21429
domains.google.com	21384
cloudflare.com	20573
gmo.jp	18110
name.com	17601
fastdomain.com	14708
register.com	13495
net.cn	12481
ionos.com	12416
ovh.com	12416
gandi.net	12305
registrar.amazon.com	12111

Host Informations

Check all domain's dns records

See Web Sites Hosted on 172.67.182.177

Fetching Web Sites Hosted

Site Inspections

Port Scanner (IP: 172.67.182.177)

› Ftp: 21

› Ssh: 22

› Telnet: 23

› Smtp: 25

› Dns: 53

› Http: 80

› Pop3: 110

› Portmapper, rpcbind: 111

› Microsoft RPC services: 135

› Netbios: 139

› Imap: 143

› Ldap: 389

› Https: 443

› SMB directly over IP: 445

› Msa-outlook: 587

› IIS, NFS, or listener RFS remote_file_sharing: 1025

› Lotus notes: 1352

› Sql server: 1433

› Point-to-point tunnelling protocol: 1723

› My sql: 3306

› Remote desktop: 3389

› Session Initiation Protocol (SIP): 5060

› Virtual Network Computer display: 5900

› X Window server: 6001

› Webcache: 8080

Spam Check (IP: 172.67.182.177)

› Dnsbl-1.uceprotect.net:

› Dnsbl-2.uceprotect.net:

› Dnsbl-3.uceprotect.net:

› Dnsbl.dronebl.org:

› Dnsbl.sorbs.net:

› Spam.dnsbl.sorbs.net:

› Bl.spamcop.net:

› Recent.dnsbl.sorbs.net:

› All.spamrats.com:

› B.barracudacentral.org:

› Bl.blocklist.de:

› Bl.emailbasura.org:

› Bl.mailspike.org:

› Bl.spamcop.net:

› Cblplus.anti-spam.org.cn:

› Dnsbl.anticaptcha.net:

› Ip.v4bl.org:

› Fnrbl.fast.net:

› Dnsrbl.swinog.ch:

› Mail-abuse.blacklist.jippg.org:

› Singlebl.spamgrouper.com:

› Spam.abuse.ch:

› Spamsources.fabel.dk:

› Virbl.dnsbl.bit.nl:

› Cbl.abuseat.org:

› Dnsbl.justspam.org:

› Zen.spamhaus.org:

Email address with orladeyo.com

Found 0 emails of this domain

Recent Searched Sites

› Kokilabenhospital.com (33 seconds ago) / US

› Ir.navitassemi.com (2 seconds ago) / US

› Rape-anma.shop (6 seconds ago) / US

› Bodyguard.nu (10 seconds ago) /

› Newsroom19.journalists.org (6 seconds ago) / US

› Jebinde.com (19 seconds ago) / US

› Busybloomingjoy.com (30 seconds ago) / US

› Synlab.com.ng (18 seconds ago) / US

› Orladeyo.com (20 seconds ago) / US

› App.shop-pro.jp (4 seconds ago) / US

› Pomelofashion.com (0 seconds ago) / SG

› Janelleperez.com (22 seconds ago) / US

› Granje.info (2 seconds ago) / US

› Etcloud.pt (10 seconds ago) / IE

› Refunds.kontur.ru (28 seconds ago) / RU

› Ellington-kamper.hubstack.net (3 seconds ago) / US

› Codafrica.org (30 seconds ago) / SG

› Murallasdepamplona.com (11 seconds ago) / ES

› Transenergylogistics.com (37 seconds ago) / RU

› Eurochlor.org (44 seconds ago) / BE

List of our tools

Emails by domain

Mobile Friendly Check

Page Speed Check

DNS Lookup

Ports Scan

Sites on host

Sitemap Generator

Websites Listing

We found Websites Listing below when search with orladeyo.com on Search Engine

Official Site for HAE Patients | ORLADEYO® (berotralstat)

If you change your mobile device number, you agree to promptly contact us at [email protected] so we can update our records and avoid having text messages inadvertently sent to an unintended recipient; Once enrolled in the Program, participants will receive approximately 30 text messages each month ; There is no fee payable to BioCryst to receive text messages; …

Orladeyo.com

Sign Up for Updates | ORLADEYO® (berotralstat)

Orladeyo.com

Speak With a Representative | ORLADEYO® (berotralstat)

Email* NPI number (10 digits) ... ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring …

Orladeyohcp.com

Join our Mentor Program | ORLADEYO® (berotralstat)

Email the completed consent form to [email protected] or fax it to 1-844-336-7693. We will identify an appropriate mentor. Empower Patient Services will introduce you to each other . All conversations will then be arranged by you and your mentor a. For additional information, contact Empower Patient Services. Call 1-866-5-EMPOWER (1-866-536-7693) Monday – Friday 8:00 …

Orladeyo.com

Patient Tools and Resources | ORLADEYO® (berotralstat)

For questions about ORLADEYO, please contact your healthcare provider or an Empower Patient Services care coordinator at 1-866-5-EMPOWER (1-866-536-7693) The Program is intended as a helpful reminder but does not constitute medical advice. You agree that the Program, including the content of the messages sent to you by it, are the property of ...

Orladeyo.com

How to Prescribe | ORLADEYO® (berotralstat)

With over 1000 prescriptions since launch, ORLADEYO is the fastest-growing therapy in hereditary angioedema (HAE). 1 Start your next patient in just 3 steps. Download the start form and fill it out. Download form. Once complete, fax or email the start form to Empower Patient Services. Fax: 1-844-336-7693. Email: [email protected].

Orladeyohcp.com

Official Site for Physicians | ORLADEYO® (berotralstat)

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is …

Orladeyohcp.com

Benefits of Attack Prevention | ORLADEYO® (berotralstat)

By agreeing to the ORLADEYO ... and use of, this Program may include your mobile device number and/or email address and related carrier information, and will be used to provide dosing reminders and relevant updates and alerts. You may also receive additional educational, marketing communications, and promotional information about BioCryst, Empower Patient …

Orladeyo.com

Orladeyo May Help Control Attacks in Patients With Normal ...

2022-02-17 · Orladeyo (berotralstat), an approved therapy for preventing swelling attacks in hereditary angiodema (HAE), was effective at controlling attacks in an HAE patient with normal C1 inhibitor activity, a case study reported.. The clinician said this oral therapy may be particularly suitable for patients who have a needle phobia and, as a result, may refuse treatment with …

Angioedemanews.com

orladeyoeventshcp.com - BioCryst

Orladeyoeventshcp.com

Orladeyo Set to Launch by Year’s End if Approved, BioCryst ...

2020-08-19 · Orladeyo is an investigational HAE treatment that works by lowering the levels of bradykinin, an inflammatory molecule that promotes swelling, the overproduction of which characterizes HAE.. Data from the clinical trials APeX-2 (NCT03485911) and APeX-S (NCT03472040, still recruiting) have demonstrated that the medication can significantly reduce …

Angioedemanews.com

ORLADEYO (berotralstat) - Home | Facebook

ORLADEYO (berotralstat) June 25 ·. This page is a great place to learn about ORLADEYO™ (berotralstat), but have you ever wanted the chance to hear about it live? Join us for an upcoming virtual educational program during which you'll be able to listen to a clinician speaker and a patient ambassador talk about their experiences with ORLADEYO.

Facebook.com

orladeyoeventspatient.com - BioCryst

Please check back for program location updates or for questions, please call 1-877-547-5640 or email [email protected]. Click here to visit the ORLADEYO website to get more information prior to joining the program. ABOUT PROGRAMS . This live educational program series on ORLADEYO ® (berotralstat) offers people living within HAE and their …

Orladeyoeventspatient.com

BioCryst Announces Preliminary Full Year 2021 ORLADEYO ...

Email Alerts; RSS News Feeds; Share Page; Press Release BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance . January 10, 2022 at 7:00 AM EST. PDF Version —ORLADEYO preliminary net revenue of $45.6 million for Q4 2021 and $122 million for FY …

Ir.biocryst.com

BioCryst to Present New ORLADEYO® (berotralstat) Data at ...

Ir.biocryst.com

Orladeyo see strong patient demand - HAE International (HAEi)

2022-01-10 · Fourth Quarter 2021 Orladeyo Launch Dynamics: New patient demand for Orladeyo remains strong and consistent, with a similar number of new patients added in Q4 2021 as in each of the previous three quarters of the year. Patients switching from other prophylactic therapies and acute-only therapy continue to drive the launch. More than half of patients new …

Haei.org

BioCryst Presents New Data Demonstrating Sustained ...

2022-02-24 · ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4 ...

Finance.yahoo.com

BioCryst Submits Marketing Authorization Application for ...

2021-03-02 · ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is …

Ca.finance.yahoo.com

BioCryst Reports Fourth Quarter and Full Year 2021 ...

2021-12-31 · — Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 — — ORLADEYO net revenue in 2022 expected to be no less than $250 million — — Pivotal trials in PNH and proof-of-concept trial in three renal indications currently enrolling patients —

Marketscreener.com

BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat ...

2020-12-04 · ORLADEYO™ (berotralstat) capsules ORLADEYO™ (berotralstat) capsules 150 mg—Significant and sustained reduction in HAE attacks— —Oral, once-daily prophylactic option enables HAE patients ...

Finance.yahoo.com

Domains Expiration Date Updated

Site	Provider	Expiration Date
razzo.io	key-systems.net	-1 Years, -171 Days
pulseintranet.com	hostingireland.ie	-1 Years, -292 Days
public-gallery-shop.com	gabia.com	1 Day
boonslickpediatrics.com	register.com	-1 Years, -305 Days
naplesbayferry.com	godaddy.com	-1 Years, -138 Days
helplogics.net	namesilo.com	236 Days
carrieroldan.com	namecheap.com	-1 Years, -246 Days
fuckingskinny.com	moniker.com	-1 Years, -130 Days
abubd.org	namesilo.com	-1 Years, -146 Days
levelonerestoration.com	godaddy.com	-1 Years, -295 Days

Browser All